Jody A. Charnow

New York

Editor at Renal & Urology News

Featured in: Favicon

renalandurologynews.com Favicon

clinicaladvisor.com Favicon

empr.com

cancertherapyadvisor.com Favicon

psychiatryadvisor.com Favicon

neurologyadvisor.com Favicon

endocrinologyadvisor.com Favicon

oncologynurseadvisor.com Favicon

infectiousdiseaseadvisor.com Favicon

dermatologyadvisor.com + 8 more

Articles

Active Surveillance Feasible for cT1b Renal Masses in Selected Patients

2 months ago | renalandurologynews.com | Jody A. Charnow

Active surveillance may be a feasible option for selected patients with 4.1-7.0 cm renal masses, data presented at the European Association of Urology’s 2025 Congress (EAU25) in Madrid, Spain, suggest. Banna Hussain, DO, MPH, of the Vattikuti Urology Institute at Henry Ford Hospital in Detroit, Michigan, and colleagues studied 1134 patients with cT1b renal masses identified using the Michigan Urological Surgery Improvement Collaborative (MUSIC) kidney registry.
UTI Incidence After Bladder Cancer Surgery Varies by Post-Op Time Point

2 months ago | renalandurologynews.com | Jody A. Charnow

The incidence of urinary tract infections (UTIs) following radical cystectomy differs by post-operative time point and patient risk factors, investigators reported at the European Association of Urology’s 40th Congress in Madrid, Spain. Maxwell Sandberg, MD, of Atrium Health, Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and colleagues retrospectively studied 386 patients who underwent radical cystectomy for bladder cancer from 2012 to 2024.
Discrepancy Common Between Clinical, Pathologic Stage After Radical Cystectomy

Mar 31, 2025 | renalandurologynews.com | Jody A. Charnow

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of patients following radical cystectomy without neoadjuvant therapy, investigators reported at the European Association of Urology’s 2025 Congress (EAU25) in Madrid, Spain.
From the Editor: A Farewell to the Readers of Renal & Urology News

Mar 31, 2025 | renalandurologynews.com | Jody A. Charnow

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the publication has chronicled a remarkable evolution in the management of genitourinary diseases. Take prostate cancer, for example.
Rectal Spacers During Prostate Radiotherapy May Preserve Erectile Function

Mar 11, 2025 | oncologynurseadvisor.com | Jody A. Charnow

Use of rectal spacers during prostate radiotherapy (RT) is associated with a lower prevalence of erectile dysfunction (ED), according to real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California. The finding is from a study that included 247,250 patients with prostate cancer receiving prostate RT (intensity-modulated RT, stereotactic body RT, brachytherapy, or proton therapy) across 3132 US counties from 2015 to 2022.
Kidney Failure Due to Kidney Stones Tied to Lower Mortality in Dialysis Population

Feb 24, 2025 | renalandurologynews.com | Jody A. Charnow

Kidney stone-related kidney failure (KF) is associated with lower mortality risk among patients on dialysis compared with other KF causes, according to a recent study of patients in Australia and New Zealand.
Real-World Data Support Enfortumab Vedotin+Pembrolizumab for Advanced Urothelial Cancer

Feb 20, 2025 | renalandurologynews.com | Jody A. Charnow

Treatment with enfortumab vedotin plus pembrolizumab (EV-P) improves outcomes in patients with locally advanced or metastatic urothelial carcinoma (UC), according to real-world data presented at the ASCO 2025 Genitourinary Cancers Symposium in San Francisco, California. The data are from a retrospective study of 120 patients treated at Mayo Clinic.
Key Factors in mRCC Cases Distinguish Prognosis Between Risk Groups

Feb 20, 2025 | renalandurologynews.com | Jody A. Charnow

Anemia and low performance status are key factors differentiating prognosis among low- and low-intermediate risk patients with metastatic renal cell carcinoma (mRCC) receiving first-line immune checkpoint inhibitor (ICI)-based therapy, according to real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.
SBRT Improves Outcomes in Oligometastatic Castration-Resistant Prostate Cancer

Feb 19, 2025 | renalandurologynews.com | Jody A. Charnow

Adding metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to standard systemic therapy for oligometastatic castration-resistant prostate cancer (CRPC) significantly improves oncologic outcomes, investigators reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.
Rectal Spacers During Prostate Radiotherapy May Preserve Erectile Function

Feb 19, 2025 | renalandurologynews.com | Jody A. Charnow

Use of rectal spacers during prostate radiotherapy (RT) is associated with a lower prevalence of erectile dysfunction (ED), according to real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California. The finding is from a study that included 247,250 patients with prostate cancer receiving prostate RT (intensity-modulated RT, stereotactic body RT, brachytherapy, or proton therapy) across 3132 US counties from 2015 to 2022.